Ranzenigo M, Gianotti N, Galli L, et al. Drug Des Devel Ther. 2022;16:1975–1982.
Page 1975, Abstract, Results, line five, the text “the ongoing regimen was based on NNRTIs in 37 (35%) and on InSTIs in 69 (65%)” should read “the ongoing regimen was based on NNRTIs in 32 (30.2%) and on InSTIs in 74 (69.8%)”.
Page 1977, Results, last paragraph, line one, the text “a longer exposure” should read “a shorter exposure”.
Page 1980, first paragraph, lines one and two, the text “(a longer history of infection and a previous diagnosis of AIDS)” should read “(a previous diagnosis of AIDS)”.
Page 1980, Table 2, last row, the category INSTI-based vs NNRTI-based for the BL ART (type of non-PI regimen) characteristic is incorrect and should read “NNRTI-based vs INSTI-based”. The correct Table 2is shown below.
Table 2.
Factors Associated with the Switch to D/C/F/TAF
| Characteristics | Category | Adjusted Hazard Ratio (95%CI) | p-value |
|---|---|---|---|
| Years of HIV | Per 1-year longer | 0.947 (0.907-0.989) | 0.014 |
| Previous diagnosis of AIDS | Yes vs. No | 3.260 (1.399-7.593) | 0.006 |
| Calendar year of BL ART | Per 1-more recent year | 2.250 (1.609-3.148) | <.0001 |
| BL triglycerides | Per 1-mg/dL higher | 1.005 (1.003-1.008) | <0.0001 |
| BL alanine transaminase | Per 1-U/L higher | 1.008 (1.003-1.012) | 0.003 |
| BL ART (type of non-PI regimen) | NNRTI-based vs INSTI-based | 0.307 (0.116-0.813) | 0.017 |
Notes: Adjusted for age, BMI, previous diagnosis of AIDS, nadir CD4+, HBV, years of HIV, calendar year of non-PI regimen start, type of nonprotease inhibitor regimen, BL CD4+, gender, HIV risk factor, HCV, previous diagnosis of diabetes, previous diagnosis of cancer, previous diagnosis of hypertension, previous or current use of statin, BL HIV-RNA, duration of HIV-RNA <50 copies/mL, BL CD4+, BL CD8+, BL CD4+/CD8+ ratio, BL hemoglobin, BL platelets, BL estimated glomerular filtrate rate, BL fasting glucose, BL triglycerides, BL total cholesterol, BL Fibrosis-4 index, BL alanine transaminase, BL aspartate transaminase, BL total bilirubin, BL alkaline phosphatase.
Abbreviations: D/C/F/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide; AIDS, acquired immune deficiency syndrome; BL, baseline; ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor.
The authors apologise for the errors and advise they do not affect the results of the paper.